Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma

Mischa de Ridder; Johannes A. Rijken; Hilde J.G. Smits; Ernst J. Smid; Patricia A.H. Doornaert; Remco de Bree

doi:10.1007/s00405-023-07904-2

Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma

Mischa de Ridder^*, Johannes A. Rijken, Hilde J.G. Smits, Ernst J. Smid, Patricia A.H. Doornaert, Remco de Bree

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose: Early-stage glottic cancer can be treated with radiotherapy only. Modern radiotherapy solutions allow for individualized dose distributions, hypofractionation and sparing of organs at risk. The target volume used to be the entire voice box. This series describe the oncological outcome and toxicity of individualized vocal cord-only hypofractionated radiotherapy for early stage (cT1a-T2 N0). Methods: Retrospective cohort study with patients treated in a single center between 2014 and 2020. Results: A total of 93 patients were included. Local control rate was 100% for cT1a, 97% for cT1b and 77% for cT2. Risk factor for local recurrence was smoking during radiotherapy. Laryngectomy-free survival was 90% at 5 years. Grade III or higher late toxicity was 3.7%. Conclusion: Vocal cord-only hypofractionated radiotherapy appears to be oncologically safe in early-stage glottic cancer. Modern, image-guided radiotherapy led to comparable results as historical series with very limited late toxicity.

Original language	English
Pages (from-to)	3345-3352
Number of pages	8
Journal	European Archives of Oto-Rhino-Laryngology
Volume	280
Issue number	7
Early online date	7 Mar 2023
DOIs	https://doi.org/10.1007/s00405-023-07904-2
Publication status	Published - Jul 2023

Keywords

Glottic cancer
Larynx
Radiotherapy
VMAT
Vocal cord

Access to Document

10.1007/s00405-023-07904-2Licence: CC BY

s00405-023-07904-2Final published version, 687 KBLicence: CC BY

Cite this

@article{c4be5070be594d66bffaa2541730571d,

title = "Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma",

abstract = "Purpose: Early-stage glottic cancer can be treated with radiotherapy only. Modern radiotherapy solutions allow for individualized dose distributions, hypofractionation and sparing of organs at risk. The target volume used to be the entire voice box. This series describe the oncological outcome and toxicity of individualized vocal cord-only hypofractionated radiotherapy for early stage (cT1a-T2 N0). Methods: Retrospective cohort study with patients treated in a single center between 2014 and 2020. Results: A total of 93 patients were included. Local control rate was 100% for cT1a, 97% for cT1b and 77% for cT2. Risk factor for local recurrence was smoking during radiotherapy. Laryngectomy-free survival was 90% at 5 years. Grade III or higher late toxicity was 3.7%. Conclusion: Vocal cord-only hypofractionated radiotherapy appears to be oncologically safe in early-stage glottic cancer. Modern, image-guided radiotherapy led to comparable results as historical series with very limited late toxicity.",

keywords = "Glottic cancer, Larynx, Radiotherapy, VMAT, Vocal cord",

author = "{de Ridder}, Mischa and Rijken, {Johannes A.} and Smits, {Hilde J.G.} and Smid, {Ernst J.} and Doornaert, {Patricia A.H.} and {de Bree}, Remco",

note = "Funding Information: None to disclose. Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jul,

doi = "10.1007/s00405-023-07904-2",

language = "English",

volume = "280",

pages = "3345--3352",

journal = "European Archives of Oto-Rhino-Laryngology",

issn = "0937-4477",

publisher = "Springer-Verlag",

number = "7",

}

TY - JOUR

T1 - Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma

AU - de Ridder, Mischa

AU - Rijken, Johannes A.

AU - Smits, Hilde J.G.

AU - Smid, Ernst J.

AU - Doornaert, Patricia A.H.

AU - de Bree, Remco

PY - 2023/7

Y1 - 2023/7

N2 - Purpose: Early-stage glottic cancer can be treated with radiotherapy only. Modern radiotherapy solutions allow for individualized dose distributions, hypofractionation and sparing of organs at risk. The target volume used to be the entire voice box. This series describe the oncological outcome and toxicity of individualized vocal cord-only hypofractionated radiotherapy for early stage (cT1a-T2 N0). Methods: Retrospective cohort study with patients treated in a single center between 2014 and 2020. Results: A total of 93 patients were included. Local control rate was 100% for cT1a, 97% for cT1b and 77% for cT2. Risk factor for local recurrence was smoking during radiotherapy. Laryngectomy-free survival was 90% at 5 years. Grade III or higher late toxicity was 3.7%. Conclusion: Vocal cord-only hypofractionated radiotherapy appears to be oncologically safe in early-stage glottic cancer. Modern, image-guided radiotherapy led to comparable results as historical series with very limited late toxicity.

AB - Purpose: Early-stage glottic cancer can be treated with radiotherapy only. Modern radiotherapy solutions allow for individualized dose distributions, hypofractionation and sparing of organs at risk. The target volume used to be the entire voice box. This series describe the oncological outcome and toxicity of individualized vocal cord-only hypofractionated radiotherapy for early stage (cT1a-T2 N0). Methods: Retrospective cohort study with patients treated in a single center between 2014 and 2020. Results: A total of 93 patients were included. Local control rate was 100% for cT1a, 97% for cT1b and 77% for cT2. Risk factor for local recurrence was smoking during radiotherapy. Laryngectomy-free survival was 90% at 5 years. Grade III or higher late toxicity was 3.7%. Conclusion: Vocal cord-only hypofractionated radiotherapy appears to be oncologically safe in early-stage glottic cancer. Modern, image-guided radiotherapy led to comparable results as historical series with very limited late toxicity.

KW - Glottic cancer

KW - Larynx

KW - Radiotherapy

KW - VMAT

KW - Vocal cord

UR - http://www.scopus.com/inward/record.url?scp=85149398631&partnerID=8YFLogxK

U2 - 10.1007/s00405-023-07904-2

DO - 10.1007/s00405-023-07904-2

M3 - Article

C2 - 36881167

SN - 0937-4477

VL - 280

SP - 3345

EP - 3352

JO - European Archives of Oto-Rhino-Laryngology

JF - European Archives of Oto-Rhino-Laryngology

IS - 7

ER -

Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this